DES health risks and precautions, from Harvard Women's Health Watch
In 1971, the FDA warned doctors to stop prescribing DES after it was linked to a rare cancer of the vagina and cervix in the daughters of women who took the drug while pregnant. Many studies since then have confirmed links between DES exposure and various health risks. Since 1992, with the DES Follow-up Study, the National Cancer Institute has been monitoring women who took DES and their daughters and sons who were exposed to it in the womb.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
